Andreas Windemuth

List of Publications by Year
in descending order

41 papers	2,810 citations	361413 20 h-index	315739 38 g-index
43 all docs	43 docs citations	43 times ranked	3857 citing authors

#	Article	IF	Citations
1	Haplotype Variation and Linkage Disequilibrium in 313 Human Genes. Science, 2001, 293, 489-493.	12.6	768
2	Combining fMRI and SNP data to investigate connections between brain function and genetics using parallel ICA. Human Brain Mapping, 2009, 30, 241-255.	3.6	237
3	Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2066-75.	7.1	207
4	On the calculation of binding free energies using continuum methods: Application to MHC class I protein–peptide interactions. Protein Science, 1997, 6, 1293-1301.	7.6	179
5	Accelerated molecular dynamics simulation with the parallel fast multipole algorithm. Chemical Physics Letters, 1992, 198, 89-94.	2.6	172
6	Gene expression analysis by transcript profiling coupled to a gene database query. Nature Biotechnology, 1999, 17, 798-803.	17.5	172
7	The fast multipole boundary element method for molecular electrostatics: An optimal approach for large systems. Journal of Computational Chemistry, 1995, 16, 898-913.	3.3	147
8	The predictive power of haplotypes in clinical response. Pharmacogenomics, 2000, 1, 15-26.	1.3	129
9	How many SNPs does a genome-wide haplotype map require?. Pharmacogenomics, 2002, 3, 379-391.	1.3	98
10	A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Research, 2007, 92, 95-102.	2.0	72
11	New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis, 2004, 177, 345-351.	0.8	61
12	Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis, 2011, 218, 451-456.	0.8	57
13	Structural coverage of the proteome for pharmaceutical applications. Drug Discovery Today, 2017, 22, 1792-1799.	6.4	51
14	Genetic Associations of Brain Structural Networks in Schizophrenia: A Preliminary Study. Biological Psychiatry, 2010, 68, 657-666.	1.3	49
15	Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site. Proteins: Structure, Function and Bioinformatics, 2018, 86, 833-843.	2.6	47
16	Genome-wide evaluation of the public SNP databases. Pharmacogenomics, 2003, 4, 779-789.	1.3	44
17	Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training. Atherosclerosis, 2006, 185, 65-69.	0.8	42
18	Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone. Clinica Chimica Acta, 2009, 400, 48-55.	1.1	35

#	ARTICLE	IF	CITATIONS
19	Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of *CYP2C9*, *CYP2C19* and *CYP2D6* genes. Biomarkers in Medicine, 2011, 5, 427-438.	1.4	28
20	Genetic Sources of Subcomponents of Event-Related Potential in the Dimension of Psychosis Analyzed From the B-SNIP Study. American Journal of Psychiatry, 2015, 172, 466-478.	7.2	23
21	CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clinica Chimica Acta, 2010, 411, 1306-1311.	1.1	19
22	Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients. Biomarkers in Medicine, 2011, 5, 439-449.	1.4	19
23	Physiogenomic Analysis of Localized fMRI Brain Activity in Schizophrenia. Annals of Biomedical Engineering, 2008, 36, 877-888.	2.5	18
24	Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethnicity and Disease, 2009, 19, 390-5.	2.3	17
25	Acetyl-coenzyme A carboxylase α gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophrenia Research, 2009, 115, 136-140.	2.0	16
26	Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474. Biochemical and Biophysical Research Communications, 2017, 483, 502-508.	2.1	15
27	Molecular dynamics simulation on a network of workstations using a machine-independent parallel programming language. Journal of Biomedical Informatics, 1992, 25, 168-180.	0.7	10
28	Multivariate Genetic Correlates of the Auditory Paired Stimuli-Based P2 Event-Related Potential in the Psychosis Dimension From the BSNIP Study. Schizophrenia Bulletin, 2016, 42, 851-862.	4.3	10
29	Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the *ACACB* gene on low-density lipoprotein cholesterol?. Pharmacogenomics, 2010, 11, 959-971.	1.3	9
30	Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing. Journal of the American Academy of Nurse Practitioners, 2011, 23, 459-463.	1.4	9
31	Novel gene-brain structure relationships in psychotic disorder revealed using parallel independent component analyses. Schizophrenia Research, 2017, 182, 74-83.	2.0	9
32	Predicting drug properties with parameter-free machine learning: pareto-optimal embedded modeling (POEM). Machine Learning: Science and Technology, 2020, 1, 025008.	5.0	9
33	Designing physiogenomic studies. Pharmacogenomics, 2006, 7, 157-158.	1.3	7
34	Proteome-Scale Drug-Target Interaction Predictions: Approaches and Applications. Current Protocols, 2021, 1, e302.	2.9	7
35	Somatic complications of psychotropic medications in a patient with multiple CYP2 drug metabolism deficiencies. Connecticut Medicine, 2007, 71, 197-200.	0.2	6
36	Laboratory Medicine in the Clinical Decision Support for Treatment of Hypercholesterolemia. Clinics in Laboratory Medicine, 2016, 36, 473-491.	1.4	5

#	Article	IF	Citations
37	Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Connecticut Medicine, 2008, 72, 399-403.	0.2	4
38	Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 36, 213-219.	4.8	3
39	Cover Image, Volume 86, Issue 8. Proteins: Structure, Function and Bioinformatics, 2018, 86, C1-C1.	2.6	0
40	Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. Puerto Rico Health Sciences Journal, 2010, 29, 402-8.	0.2	0
41	For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethnicity and Disease, 2009, 19, 479-80.	2.3	0